PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA says not yet to Ipsen rare bone disease drug

French drugmaker Ipsen announced last week that the FDA had responded to the New Drug application for its fibrodysplasia ossificans progressiva (FOP) therapy, palovarotene, with a Complete Response Letter.

According to the company’s statement, the CRL is related to a previous request that the agency had made for additional information on palovarotene’s clinical data. The request had been communicated in October 2022, and Ipsen anticipates responding within the first quarter of next year. While no specific details were disclosed concerning the data requests, Ipsen said it is “not a request for additional efficacy or safety data beyond existing studies.”

Palovarotene belongs to a class of medications known as retinoids, similar in mechanism to other drugs which are derivatives of vitamin A. The oral drug was first approved for use in Canada in January 2022, making it the first global approval for any FOP therapy. While it has received Rare Pediatric Disease and Breakthrough Therapy designations from the FDA, its road to approval in the United States has been bumpy, to say the least. FOP is a rare, bone and tissue disorder that causes bone formation outside of the skeleton and in connective tissue.

The drug was initially developed by Canadian biopharma Clementia and was perhaps the most important incentive to Ipsen when it decided to buy all outstanding shares of the company in 2019, looking to bolster its rare disease portfolio.

In May 2021, Ipsen confirmed that the FDA had accepted its NDA for the drug, only to announce a few months later that the application had been withdrawn. At the time, the company said that during the review and ongoing dialogue with the FDA, “it was recognized that additional analyses and evaluation of data collected from Ipsen’s Phase III MOVE and FOP program would be required to progress.”

It was agreed between Ipsen and the FDA that it would not be possible to complete this within the current NDA review cycle Since then, the drug received a Priority Review in January 2022. Now, due to pending requests, the FDA will be evaluating the resubmission of the NDA once more.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026